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RT, histological grade, tumour size or nodal stage. However, 
patients carrying the LAMP3 rs482912 SNP either 
homozygously (n=323) or heterozygously (n=253) had fewer 
locoregional recurrences than those carrying the reference 
allele (n=50, Hazard Ratio (HR) = 0.389, 95% Confidence 
Interval (CI) = 0.196-0.771, P = .007) (figure). This prognostic 
value was limited to patients treated with breast-conserving 
therapy including RT (HR = 0.265, CI = 0.104-0.674, P = .005), 
which is in line with a role for LAMP3 in radiosensitivity. 
Furthermore, the LAMP3 SNP was only prognostic in grade III 
tumours (HR = 0.270, P = .005), tumours larger than 2 cm (HR 
= 0.357, P = .011), and in patients with involved lymph nodes 
(HR = 0.154, P < .001). 
 
Figure: Breast cancer patients that carry the LAMP3 rs482912 
SNP allele (C) either homozygously or heterozygously have 
better locoregional control (P = .007). 
Conclusions: The LAMP3 rs482912 SNP is associated with 
locoregional control in a cohort of 626 breast cancer 
patients. This is specifically the case after RT as part of 
breast conserving treatment and for patients with more 
advanced or aggressive tumours.  
   
OC-0398   
HSPB1 rs2868370 predicts risk of relapse in patients with 
lung cancer treated with radio(chemo)therapy  
J.L. Lopez Guerra1, M. Perez2, S. Perez Luque2, L. Delgado 
Arroniz2, E. Montero1, R. Peñalver Jiménez1, C.M. Fuentes 
Madrid1, M. González Oliveros1, J.M. Praena-Fernandez3, M.J. 
Ortiz Gordillo1 
1Virgen del Rocio University Hospital, Radiation oncology, 
Sevilla, Spain  
2Instituto de Biomedicina de Sevilla,  
BIS/HUVR/CSIC/Universidad de Sevilla, Sevilla, Spain  
3Virgen del Rocio University Hospital, Methodology Unit- 
Fundación Pública Andaluza para la Gestión de la 
Investigación en Salud de Sevilla, Sevilla, Spain  
 
Purpose/Objective: The incidence of relapse of locally 
advanced lung cancer after treatment with radio(chemo) 
therapy is still high. The significance of biologic markers such 
as heat shock protein (HSPB1) for predicting recurrence has 
been increasingly emphasized by recent investigations. We 
investigated prospectively the association between single 
nucleotide polymorphisms (SNPs) in the HSPB1 gene and the 
risk of relapse in patients with lung cancer. 
Materials and Methods: The data set consist of 156 lung 
cancer patients with available genomic DNA samples and 
treated with radio(chemo)therapy from January 2013 to 
September 2014. Median age was 63 years-old (range, 37-89) 
and the Karnofsky performance status was ≥70 except for 6 
cases. The most common histology for non-small cell lung 
cancer patients (79%) was squamous cell carcinoma (65%). 
Seventythree percent of patients had Stage III disease, 92.3% 
received platinum-based chemotherapy, and received doses 
between 39 Gy and 70 Gy (median, 63 Gy). We genotyped 
three SNPs of the HSPB1 gene (rs2868370, rs2868371, and 
rs7459185) by the TaqMan assays. Cox proportional hazards 
analysis was performed to calculate the hazard ratio (HR) and 
confidence interval (CI) of each genotype on relapse risk. 
Multivariate analyses were performed using a logistic 
regression model, with a stepwise backward elimination 
procedure. A P value of 0.05 or less was considered 
statistically significant. 
Results: The distribution of the HSPB1 genotype was: 
rs2868370, 65% GG, 32% AG, 3% AA; rs2868371, 77% CC, 18% 
CG, 5% GG; rs7459185, 51% GG, 39% CG, 10% GG).The 
incidence of relapse was 31% (24% locoregional and distant, 
18% only locoregional, and 58% only distant). In univariate 
analysis, CG/GG genotypes of HSPB1 rs2868371 were 
associated with a statistically significantly lower risk of any 
relapse (HR = 0.47; 95% CI, 0.23 to 0.97; p = 0.042) and 
distant recurrence (HR = 0.40; 95% CI, 0.17-0.93; p = 0.033) 
compared with the CC genotype. In addition, AG/AA 
genotypes of HSPB1 rs2868370 were associated with a 
statistically significantly higher risk of distant relapse (HR = 
2.19; 95% CI, 1.11 to 4.35; p = 0.024) compared with the GG 
genotype. In multivariate analysis, only the rs2868370 SNP 
retained significance (HR = 2.47; p = 0.010). 
Conclusions: Our results showed that the AG/GG genotypes 
of HSPB1 rs2868370 gene were associated with a higher risk 
of distant relapse in patients with lung cancer treated with 
radio(chemo)therapy and thus may serve as a reliable 
predictor of recurrence. This response marker may be used 
for guiding therapy intensity or as a selection criteria for a 
clinical trial in an individual patient, which would further the 
goal of individualized therapy.  
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Purpose/Objective: In a former study (1), the hypoxia gene 
expression classifier, developed in head and neck squamous 
cell carcinomas, was applied in 89 patients with loco-regional 
gastroesophageal cancer (GC). Analysis of the 15 genes was 
indicative of hypoxia being more profound in esophagus 
squamous cell carcinomas (ESCC) compared with 
adenocarcinomas of the esophago-gastric junction and the 
stomach (AC), and was a potential prognostic marker in 
patients with ESCC. The purpose of the present study was to 
confirm these results. 
Materials and Methods: The study population consisted of 
152 patients with GC treated with neoadjuvant or definitive 
chemoradiotherapy or perioperative chemotherapy. Based on 
formalin-fixed, paraffin-embedded, diagnostic biopsies, gene 
expression of the 15 hypoxia-induced and pH-independent 
genes was obtained with qPCR. Sufficient amounts of RNA for 
gene analyses were available in 135 patients; ESCC: 89 
